Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBI-8000 with Paclitaxel and Trastuzumab in HER2+ Breast Cancer
NCT02569489Phase 1Withdrawn
- Sponsor
- HUYABIO International, LLC
- Start
- Dec 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tucidinostat in breast cancer, sponsored by HUYABIO International, LLC. Primary endpoint: Maximum Tolerated Dose at 28 days. Planned start Dec 2015; status: withdrawn.
02
Drugs
tucidinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02569489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02569489.